

Barry L Carter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2617749/publications.pdf>

Version: 2024-02-01

133
papers

12,531
citations

71102

41
h-index

24258

110
g-index

134
all docs

134
docs citations

134
times ranked

13863
citing authors

#	ARTICLE	IF	CITATIONS
1	2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. JAMA - Journal of the American Medical Association, 2014, 311, 507.	7.4	6,625
2	Thiazide Diuretics, Potassium, and the Development of Diabetes. Hypertension, 2006, 48, 219-224.	2.7	405
3	Comparative Antihypertensive Effects of Hydrochlorothiazide and Chlorthalidone on Ambulatory and Office Blood Pressure. Hypertension, 2006, 47, 352-358.	2.7	391
4	The Potency of Team-Based Care Interventions for Hypertension. Archives of Internal Medicine, 2009, 169, 1748-55.	3.8	294
5	Hydrochlorothiazide Versus Chlorthalidone. Hypertension, 2004, 43, 4-9.	2.7	280
6	Physician and Pharmacist Collaboration to Improve Blood Pressure Control. Archives of Internal Medicine, 2009, 169, 1996.	3.8	258
7	A Cluster Randomized Trial to Evaluate Physician/Pharmacist Collaboration to Improve Blood Pressure Control. Journal of Clinical Hypertension, 2008, 10, 260-271.	2.0	184
8	Influential Characteristics of Physician/Pharmacist Collaborative Relationships. Annals of Pharmacotherapy, 2004, 38, 764-770.	1.9	144
9	Thiazide and Loop Diuretics. Journal of Clinical Hypertension, 2011, 13, 639-643.	2.0	134
10	Clinical and Economic Impact of Ambulatory Care Clinical Pharmacists in Management of Dyslipidemia in Older Adults: The IMPROVE Study. Pharmacotherapy, 2000, 20, 1508-1516.	2.6	125
11	The Hypertension Team: The Role of the Pharmacist, Nurse, and Teamwork in Hypertension Therapy. Journal of Clinical Hypertension, 2012, 14, 51-65.	2.0	119
12	Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.6	118
13	Comprehensive Pharmaceutical Care in the Chain Setting. Journal of the American Pharmacists Association, 1996, 36, 443-451.	0.5	111
14	Meta-Analysis of Dose-Response Characteristics of Hydrochlorothiazide and Chlorthalidone: Effects on Systolic Blood Pressure and Potassium. American Journal of Hypertension, 2010, 23, 440-446.	2.0	106
15	Thiazide-Induced Dysglycemia. Hypertension, 2008, 52, 30-36.	2.7	105
16	The Relationship between Drug Therapy Noncompliance and Patient Characteristics, Health-Related Quality of Life, and Health Care Costs. Pharmacotherapy, 2000, 20, 941-949.	2.6	102
17	Measuring Adherence to Practice Guidelines for the Management of Hypertension. Hypertension, 2004, 44, 602-608.	2.7	102
18	Cluster-Randomized Trial of a Physician/Pharmacist Collaborative Model to Improve Blood Pressure Control. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 235-243.	2.2	99

#	ARTICLE	IF	CITATIONS
19	Pharmacist-Physician Comanagement of Hypertension and Reduction in 24-Hour Ambulatory Blood Pressures. <i>Archives of Internal Medicine</i> , 2010, 170, 1634.	3.8	84
20	Evolution of Clinical Pharmacy in the USA and Future Directions for Patient Care. <i>Drugs and Aging</i> , 2016, 33, 169-177.	2.7	81
21	Research Needs to Improve Hypertension Treatment and Control in African Americans. <i>Hypertension</i> , 2016, 68, 1066-1072.	2.7	78
22	Development and Initial Validation of an Instrument to Measure Physician-Pharmacist Collaboration from the Physician Perspective. <i>Value in Health</i> , 2005, 8, 59-66.	0.3	76
23	An Economic Analysis of a Randomized, Controlled, Multicenter Study of Clinical Pharmacist Interventions for High-Risk Veterans: The IMPROVE Study. <i>Pharmacotherapy</i> , 2000, 20, 1149-1158.	2.6	74
24	Evaluation of the Iowa Medicaid Pharmaceutical Case Management Program. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2004, 44, 337-349.	1.5	73
25	Cost-Effectiveness of a Physician-Pharmacist Collaboration Intervention to Improve Blood Pressure Control. <i>Hypertension</i> , 2015, 66, 1145-1151.	2.7	70
26	Description of pharmacist interventions during physician-pharmacist co-management of hypertension. <i>International Journal of Clinical Pharmacy</i> , 2007, 30, 128-135.	1.4	66
27	Team-Based Care with Pharmacists to Improve Blood Pressure: a Review of Recent Literature. <i>Current Hypertension Reports</i> , 2018, 20, 1.	3.5	66
28	Comparison of Nifedipine Alone and With Diltiazem or Verapamil in Hypertension. <i>Hypertension</i> , 1996, 28, 109-114.	2.7	63
29	Evaluation of Pharmacists' Work in a Physician-Pharmacist Collaborative Model for the Management of Hypertension. <i>Pharmacotherapy</i> , 2016, 36, 374-384.	2.6	62
30	Effect of clinical pharmacist intervention on medication discrepancies following hospital discharge. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 430-437.	2.1	61
31	Patient and Physician Beliefs About Control over Health: Association of Symmetrical Beliefs with Medication Regimen Adherence. <i>Journal of General Internal Medicine</i> , 2010, 25, 397-402.	2.6	60
32	Effect of a care transition intervention by pharmacists: an RCT. <i>BMC Health Services Research</i> , 2014, 14, 406.	2.2	60
33	Can Clinical Pharmacists Affect SF-36 Scores in Veterans at High Risk for Medication-Related Problems?. <i>Medical Care</i> , 2001, 39, 113-122.	2.4	59
34	Explicit and Implicit Evaluation of Physician Adherence to Hypertension Guidelines. <i>Journal of Clinical Hypertension</i> , 2007, 9, 113-119.	2.0	57
35	How Pharmacists Can Assist Physicians With Controlling Blood Pressure. <i>Journal of Clinical Hypertension</i> , 2003, 5, 31-37.	2.0	55
36	Increasing Trend in Admissions for Malignant Hypertension and Hypertensive Encephalopathy in the United States. <i>Hypertension</i> , 2015, 65, 1002-1007.	2.7	54

#	ARTICLE	IF	CITATIONS
37	Physician-Pharmacist Collaborative Management of Asthma in Primary Care. <i>Pharmacotherapy</i> , 2014, 34, 1033-1042.	2.6	51
38	Deterioration of Blood Pressure Control After Discontinuation of a Physician-Pharmacist Collaborative Intervention. <i>Pharmacotherapy</i> , 2010, 30, 228-235.	2.6	50
39	Types of Interventions Made by Clinical Pharmacists in the IMPROVE Study. <i>Pharmacotherapy</i> , 2000, 20, 429-435.	2.6	49
40	Efficacy and Safety of Nighttime Dosing of Antihypertensives: Review of the Literature and Design of a Pragmatic Clinical Trial. <i>Journal of Clinical Hypertension</i> , 2014, 16, 115-121.	2.0	48
41	Interpreting the findings of the IMPROVE study. <i>American Journal of Health-System Pharmacy</i> , 2001, 58, 1330-1337.	1.0	42
42	Eplerenone – A Novel Selective Aldosterone Blocker. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1567-1576.	1.9	40
43	All Thiazide-Like Diuretics Are Not Chlorthalidone: Putting the ACCOMPLISH Study Into Perspective. <i>Journal of Clinical Hypertension</i> , 2009, 11, 5-10.	2.0	40
44	Ambulatory Care Pharmacy Services: Has the Agenda Changed?. <i>Annals of Pharmacotherapy</i> , 2000, 34, 772-787.	1.9	39
45	A Cluster-Randomized Effectiveness Trial of a Physician-Pharmacist Collaborative Model to Improve Blood Pressure Control. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 418-423.	2.2	38
46	Comparative Effectiveness Research: Evaluating Pharmacist Interventions and Strategies to Improve Medication Adherence. <i>American Journal of Hypertension</i> , 2010, 23, 949-955.	2.0	38
47	Outpatient blood pressure monitoring using bi-directional text messaging. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 375-381.	2.3	37
48	Ambulatory Care Pharmacy Services: The Incomplete Agenda. <i>Annals of Pharmacotherapy</i> , 1992, 26, 701-708.	1.9	36
49	Effect of Self-Efficacy and Social Support on Adherence to Antihypertensive Drugs. <i>Pharmacotherapy</i> , 2010, 30, 432-441.	2.6	35
50	Sustained Blood Pressure Control Following Discontinuation of a Pharmacist Intervention. <i>Journal of Clinical Hypertension</i> , 2011, 13, 431-437.	2.0	35
51	Physician-Pharmacist Collaborative Management. <i>Hypertension</i> , 2016, 68, 1314-1320.	2.7	35
52	Pharmacist Intervention for Blood Pressure Control in Patients with Diabetes and/or Chronic Kidney Disease. <i>Pharmacotherapy</i> , 2018, 38, 309-318.	2.6	35
53	Implementing the New Guidelines for Hypertension. <i>Journal of Managed Care Pharmacy</i> , 2004, 10, S18-S25.	2.2	34
54	Formation of a primary care pharmacist practice-based research network. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 2044-2049.	1.0	33

#	ARTICLE	IF	CITATIONS
55	Extent of Services Provided by Pharmacists in the Iowa Medicaid Pharmaceutical Case Management Program. <i>Journal of the American Pharmacists Association</i> , 2003, 43, 24-33.	0.5	32
56	Assessing the structure and process for providing pharmaceutical care in Veterans Affairs medical centers. <i>American Journal of Health-System Pharmacy</i> , 2000, 57, 29-39.	1.0	31
57	Cluster-Randomized Trial to Evaluate a Centralized Clinical Pharmacy Service in Private Family Medicine Offices. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004188.	2.2	31
58	Pharmacist intervention for blood pressure control: medication intensification and adherence. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 569-578.	2.3	30
59	The IMPROVE study: Background and study design. <i>American Journal of Health-System Pharmacy</i> , 1998, 55, 62-67.	1.0	29
60	Characteristics of ambulatory care clinics and pharmacists in Veterans Affairs medical centers. <i>American Journal of Health-System Pharmacy</i> , 1998, 55, 68-72.	1.0	28
61	Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 307-317.	2.3	28
62	Physician Adherence to Blood Pressure Guidelines and Its Effect on Seniors. <i>Pharmacotherapy</i> , 2008, 28, 843-851.	2.6	27
63	Physician-Pharmacist Co-Management and 24-Hour Blood Pressure Control. <i>Journal of Clinical Hypertension</i> , 2013, 15, 337-343.	2.0	27
64	The Role of Pharmacists in the Detection, Management, and Control of Hypertension: A National Call To Action. <i>Pharmacotherapy</i> , 2000, 20, 119-122.	2.6	26
65	The extent of potential antihypertensive drug interactions in a Medicaid population. <i>American Journal of Hypertension</i> , 2002, 15, 953-957.	2.0	26
66	Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care. <i>Journal of Hypertension</i> , 2017, 35, 178-187.	0.5	26
67	Primary Care Physician-Pharmacist Collaborative Care Model: Strategies for Implementation. <i>Pharmacotherapy</i> , 2016, 36, 363-373.	2.6	25
68	The Iowa Continuity of Care study: Background and methods. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 1631-1642.	1.0	24
69	Patient and Provider Perceptions of Hypertension Treatment: Do They Agree?. <i>Journal of Clinical Hypertension</i> , 2007, 9, 416-423.	2.0	23
70	Incremental Costs Associated with Physician and Pharmacist Collaboration to Improve Blood Pressure Control. <i>Pharmacotherapy</i> , 2012, 32, 772-780.	2.6	23
71	Acceptance of Recommendations by Inpatient Pharmacy Case Managers: Unintended Consequences of Hospitalist and Specialist Care. <i>Pharmacotherapy</i> , 2013, 33, 11-21.	2.6	23
72	Development and Reliability Testing of the Clinical Pharmacist Recommendation Taxonomy. <i>Pharmacotherapy</i> , 2007, 27, 639-646.	2.6	21

#	ARTICLE	IF	CITATIONS
73	Evaluation of Family Physician Prescribing: Influence of the Clinical Pharmacist. <i>Drug Intelligence & Clinical Pharmacy</i> , 1984, 18, 817-821.	0.4	20
74	Underutilization of cardiovascular medications: Effect of a continuity-of-care program. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1592-1600.	1.0	20
75	Postabsorption Concentration Peaks with Brand Name and Generic Verapamil: A Double-Blind, Crossover Study in Elderly Hypertensive Patients. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 526-534.	2.0	18
76	Efficacy of Patient Activation Interventions With or Without Financial Incentives to Promote Prescribing of Thiazides and Hypertension Control. <i>JAMA Network Open</i> , 2018, 1, e185017.	5.9	17
77	Antihypertensive Drug Utilization in Hypertensive Veterans With Complex Medication Profiles. <i>Journal of Clinical Hypertension</i> , 2000, 2, 172-180.	2.0	17
78	Using theory to predict implementation of a physician-pharmacist collaborative intervention within a practice-based research network. <i>Research in Social and Administrative Pharmacy</i> , 2013, 9, 719-730.	3.0	16
79	Self-identified barriers to rural mental health services in Iowa by older adults with multiple comorbidities: qualitative interview study. <i>BMJ Open</i> , 2019, 9, e029976.	1.9	16
80	Development of a computer algorithm for defining an active drug list using an automated pharmacy database. <i>Journal of Clinical Epidemiology</i> , 2003, 56, 802-806.	5.0	15
81	Selection bias and subject refusal in a cluster-randomized controlled trial. <i>BMC Medical Research Methodology</i> , 2017, 17, 94.	3.1	15
82	Atherosclerotic Renal Artery Stenosis and Renovascular Hypertension: Clinical Diagnosis and Indications for Revascularization. <i>Journal of Clinical Hypertension</i> , 2006, 8, 481-486.	2.0	14
83	A centralized cardiovascular risk service to improve guideline adherence in private primary care offices. <i>Contemporary Clinical Trials</i> , 2015, 43, 25-32.	1.8	14
84	A Mixed-Method Approach to Evaluate a Pharmacist Intervention for Veterans With Hypertension. <i>Journal of Clinical Hypertension</i> , 2014, 16, 133-140.	2.0	12
85	A Cluster-Randomized Trial of a Centralized Clinical Pharmacy Cardiovascular Risk Service to Improve Guideline Adherence. <i>Pharmacotherapy</i> , 2015, 35, 653-662.	2.6	12
86	Optimizing delivery systems to tailor pharmacotherapy to cardiovascular circadian events. <i>American Journal of Health-System Pharmacy</i> , 1998, 55, S17-S23.	1.0	11
87	Development of Diabetes With Thiazide Diuretics: The Potassium Issue. <i>Journal of Clinical Hypertension</i> , 2005, 7, 638-640.	2.0	11
88	Reduction in Adverse Symptoms as Blood Pressure Becomes Controlled. <i>Pharmacotherapy</i> , 2008, 28, 1104-1114.	2.6	11
89	Similar Blood Pressure Values Across Racial and Economic Groups: Baseline Data from a Group Randomized Clinical Trial. <i>Journal of Clinical Hypertension</i> , 2013, 15, 404-412.	2.0	11
90	Avoiding Pitfalls With Implementation of Randomized Controlled Multicenter Trials: Strategies to Achieve Milestones. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	11

#	ARTICLE	IF	CITATIONS
91	Once-Daily Propranolol for Hypertension: A Comparison of Regular-Release, Long-Acting, and Generic Formulations. <i>Pharmacotherapy</i> , 1989, 9, 17-22.	2.6	10
92	A longitudinal analysis of antihypertensive drug interactions in a Medicaid population. <i>American Journal of Hypertension</i> , 2004, 17, 421-427.	2.0	10
93	Adherence, Quality of Life, Cost Effectiveness, and the Role of the Pharmacist. , 2007, , 1119-1127.		10
94	Role of collaborative care models including pharmacists in improving blood pressure management in chronic kidney disease patients. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 498-503.	2.0	10
95	Sustained Blood Pressure Control Following Discontinuation of a Pharmacist Intervention for Veterans. <i>Journal of Clinical Hypertension</i> , 2015, 17, 701-708.	2.0	10
96	Cluster randomized trials for pharmacy practice research. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 607-614.	2.1	10
97	Designing Quality Health Services Research: Why Comparative Effectiveness Studies Are Needed and Why Pharmacists Should Be Involved. <i>Pharmacotherapy</i> , 2010, 30, 751-757.	2.6	9
98	Institutional Review Board Barriers and Solutions Encountered in the Collaboration Among Pharmacists and Physicians to Improve Outcomes Now Study: A National Multicenter Practice-Based Implementation Trial. <i>Pharmacotherapy</i> , 2013, 33, 902-911.	2.6	9
99	The Clinical Pharmacy Specialist: Part of the Solution. <i>Journal of General Internal Medicine</i> , 2017, 32, 375-377.	2.6	9
100	A texting-based blood pressure surveillance intervention. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1463-1470.	2.0	9
101	Effect of a Physician/Pharmacist Collaborative Care Model on Time in Target Range for Systolic Blood Pressure: Post Hoc Analysis of the CAPTION Trial. <i>Hypertension</i> , 2021, 78, 966-972.	2.7	8
102	Dual Calcium-Channel Blocker Therapy in the Treatment of Hypertension. <i>Annals of Pharmacotherapy</i> , 1996, 30, 802-810.	1.9	7
103	Blood Pressure as a Surrogate End Point for Hypertension. <i>Annals of Pharmacotherapy</i> , 2002, 36, 87-92.	1.9	6
104	Antihypertensive drug interactions. <i>Drugs of Today</i> , 2005, 41, 55.	2.4	5
105	Antihypertensive Prescribing. <i>Hypertension</i> , 2006, 48, 816-817.	2.7	4
106	Strategies to improve the cardiovascular risk profile of thiazide-type diuretics as used in the management of hypertension. <i>Expert Opinion on Drug Safety</i> , 2007, 6, 583-594.	2.4	4
107	Guidelines for Use of Diuretics: A View From a Member of JNC 7. <i>Journal of Clinical Hypertension</i> , 2012, 14, 273-276.	2.0	4
108	Collaborative care model for hypertension. <i>Journal of Clinical Hypertension</i> , 2018, 20, 96-97.	2.0	4

#	ARTICLE	IF	CITATIONS
109	The Cardiovascular Effects of Treatment with Hydroxychloroquine and Azithromycin. <i>Pharmacotherapy</i> , 2020, 40, 978-983.	2.6	4
110	A pharmacist intervention for monitoring and treating hypertension using bidirectional texting: PharmText BP. <i>Contemporary Clinical Trials</i> , 2020, 98, 106169.	1.8	4
111	Development of clinical pharmacy quality measures: A call to action. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2022, 5, 366-369.	1.0	4
112	Why Physicians Do Not Prescribe a Thiazide Diuretic. <i>Journal of Clinical Hypertension</i> , 2010, 12, 502-507.	2.0	3
113	Instrumental variable methods to assess quality of care the marginal effects of process-of-care on blood pressure change and treatment costs. <i>Research in Social and Administrative Pharmacy</i> , 2015, 11, e69-e83.	3.0	3
114	Dissemination of a telehealth cardiovascular risk service: The CVRS live protocol. <i>Contemporary Clinical Trials</i> , 2021, 102, 106282.	1.8	3
115	Thiazide-Induced Hyperglycemia: Can It Be Prevented?. <i>American Journal of Hypertension</i> , 2009, 22, 473-473.	2.0	2
116	Diuretics in Hypertension. , 2018, , 211-221.		2
117	Longitudinal analysis of antihypertensive drug interactions. <i>American Journal of Hypertension</i> , 2003, 16, A13.	2.0	1
118	Selection of explicit criteria for a JNC-7 guideline adherence tool. <i>American Journal of Hypertension</i> , 2004, 17, S144.	2.0	1
119	Physician adherence to JNC 7 guidelines and blood pressure control. <i>American Journal of Hypertension</i> , 2005, 18, A190-A190.	2.0	1
120	Fixedâ€Dosed Combinations Are Not Indicated as Initial Therapy: A Debate. <i>Journal of Clinical Hypertension</i> , 2009, 11, 94-99.	2.0	1
121	Have we been true to Paul Parker's vision? Paul F. Parker Medal for Distinguished Service to the Profession of Pharmacy remarks. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 92-94.	1.0	1
122	Targeting of uncontrolled hypertension in the emergency department (TOUCHED): Design of a randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2021, 102, 106283.	1.8	1
123	Adherence to Hypertension Treatments. , 0, , 253-266.		1
124	Extent of services provided by pharmacists in the Iowa Medicaid Pharmaceutical Case Management program. <i>Journal of the American Pharmacists Association</i> , 2003, 43, 24-33.	0.5	1
125	Association between Appropriateness of Prescribing and Prescription Documentation. <i>American Journal of Health-System Pharmacy</i> , 1983, 40, 1513-1515.	1.0	0
126	Diuretic Therapy in Cardiovascular Disease. , 2013, , 160-171.		0

#	ARTICLE	IF	CITATIONS
127	Will Team-Based Care Really Be Implemented?. Journal of Clinical Hypertension, 2015, 17, 692-693.	2.0	0
128	Development of a centralized, remote clinical pharmacy service to enhance primary care. Pharmacy Practice, 2021, 19, 2348.	1.5	0
129	A cluster randomized trial to evaluate a centralized remote clinical pharmacy service in large, health system primary care clinics. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1287.	1.0	0
130	Team-Based Care for the Management of Hypertension. , 2013, , 397-404.		0
131	Team-Based Care for Hypertension Management. , 2018, , 443-451.		0
132	Hypertension: a review of therapeutic options. Managed Care, 2003, 12, 34-44.	0.3	0
133	Antihypertensive drug interactions. Timely Topics in Medicine Cardiovascular Diseases [electronic Resource], 2005, 9, E2.	0.1	0